US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

LB Pharmaceuticals

37.22

+2.617.54%

Post-market: 37.220.00000.00%19:30 EDT

Volume:642.58K

Turnover:24.00M

Market Cap:1.20B

PE:-12.46

High:38.50

Open:35.01

Low:35.01

Close:34.61

52wk High:50.16

52wk Low:14.32

Shares:32.26M

Float Shares:21.62M

Volume Ratio:1.50

T/O Rate:2.97%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.9880

EPS(LYR):-3.1329

ROE:-50.00%

ROA:-29.98%

PB:3.61

PE(LYR):-11.88

Loading ...

Overview Company News Filings

LB Pharmaceuticals Advances LB-102 into Phase 3 Schizophrenia Trial NOVA-2

LB Pharmaceuticals Presents New Preclinical Data Supporting LB-102’s Bimodal Mechanism of Action and Highlights Ongoing Late-Stage Clinical Development Programs at the 39th ECNP Congress

LB Pharmaceuticals Grants 200,000-Share Option Inducement Awards to New CMO, CFO

Lb Pharmaceuticals Reports Inducement Grants to New Employee Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS

LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Lb Pharmaceuticals Inc : Canaccord Genuity Initiates Coverage with Buy Rating; Target Price $65

THOMSON REUTERS

Canaccord Genuity Initiates LB Pharmaceuticals at Buy With $65 Price Target

MT Newswires Live

LB Pharmaceuticals to Host In-Person and Virtual R&D Day on October 27, 2026: Advancing LB‑102 with a Focus on Schizophrenia Treatment

Guggenheim stats LB Pharmaceuticals at Buy, calls best idea

LB Pharmaceuticals Price Target Cut to $35.00/Share from $37.00 by Roth Capital

LB Pharmaceuticals downgraded to Neutral from Buy at Roth Capital

Needham Initiates LB Pharmaceuticals at Buy With $68 Price Target

MT Newswires Live

LB Pharmaceuticals Initiated at Buy by Needham

LB Pharmaceuticals initiated with a Buy at Needham

Analyst Initiates Buy Rating on LB-102 for De-Risked Antipsychotic Profile, Multi-Indication Potential and Strong Long-Term Revenue Outlook

Lb Pharmaceuticals Inc : Needham Initiates Coverage with Buy Rating; Target Price $68

THOMSON REUTERS

Lb Pharmaceuticals Inc Files for Mixed Shelf; Size not Disclosed - SEC Filing

THOMSON REUTERS

LB Pharmaceuticals’ Chief Medical Officer Susan Gani Kozauer Files Initial Beneficial Ownership Statement (Form 3)

Lb Pharmaceuticals Appoints Susan G. Kozauer, M.d. as Chief Medical Officer

THOMSON REUTERS

Press Release: LB Pharmaceuticals Appoints Susan G. Kozauer, M.D. as Chief Medical Officer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/LBRX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"LBRX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LBRX\",,,,,undefined,":{"symbol":"LBRX","market":"US","secType":"STK","nameCN":"LB Pharmaceuticals","latestPrice":37.22,"timestamp":1791576000000,"preClose":34.61,"halted":0,"volume":642582,"hourTrading":{"tag":"盘后","latestPrice":37.22,"preClose":37.22,"latestTime":"19:30 EDT","volume":3280,"amount":122081.44,"timestamp":1791588606170,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.07541173071366655,"floatShares":21621800,"shares":32259175,"eps":-2.988,"marketStatus":"Market Closed","change":2.61,"latestTime":"10-09 16:00:00 EDT","open":35.01,"high":38.5,"low":35.01,"amount":23997490.176366,"amplitude":0.100838,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.988,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791792000000},"marketStatusCode":7,"adr":0,"listingDate":1757563200000,"exchange":"NASDAQ","adjPreClose":34.61,"preHourTrading":{"tag":"盘前","latestPrice":35.99,"preClose":34.61,"latestTime":"05:36 EDT","volume":87,"amount":3131.13,"timestamp":1791538564916,"change":1.38,"changeRate":0.039873,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":37.22,"preClose":37.22,"latestTime":"19:30 EDT","volume":3280,"amount":122081.44,"timestamp":1791588606170,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.5000672324175153,"impliedVol":0.7201,"impliedVolPercentile":0.5914},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LBRX\",,,,,undefined,":{"symbol":"LBRX","floatShares":21621800,"roa":"-29.98%","roe":"-50.00%","lyrEps":-3.132945,"volumeRatio":1.5000672324175153,"shares":32259175,"dividePrice":0,"high":38.5,"amplitude":0.100838,"preClose":34.61,"low":35.01,"week52Low":14.3166,"pbRate":"3.61","week52High":50.16,"institutionHeld":0,"latestPrice":37.22,"eps":-2.988,"divideRate":0,"volume":642582,"delay":0,"ttmEps":-2.988,"open":35.01,"prevYearClose":22.26,"prevWeekClose":36.99,"prevMonthClose":38.38,"prevQuarterClose":38.38,"fiveDayClose":36.99,"twentyDayClose":44.63,"sixtyDayClose":30.59},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LBRX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-11","symbol":"LBRX","fiscalQuarterEnding":"2026/06","expectedEps":-0.84,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786420800000,"reportTimeType":"pre","actualEps":-1.71},{"market":"US","date":"2026-05-12","symbol":"LBRX","fiscalQuarterEnding":"2026/03","expectedEps":-0.75,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778558400000,"reportTimeType":"post","actualEps":-0.67},{"market":"US","date":"2026-03-26","symbol":"LBRX","fiscalQuarterEnding":"2025/12","expectedEps":-0.45,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774497600000,"reportTimeType":"post","actualEps":-0.45}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LBRX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LBRX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.5833,"hold":0.0833,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5833,"analysts":12,"updateTime":1791259200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LBRX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LBRX","date":"2026-10-09","current":-12.456493,"percent":0.844444,"low":-37.407457,"twenty":-31.657513,"median":-23.572675,"eighty":-15.865106,"high":-0.410019,"avg":-23.310412,"sd":7.623561,"marketCap":1116490046},"quantilePoints":[{"date":"2025-09-12","current":-13.187639,"twenty":-10.632115,"median":-6.798829,"eighty":-2.965543,"marketCap":388099031},{"date":"2025-09-19","current":-12.217088,"twenty":-12.798201,"median":-12.438246,"eighty":-12.070666,"marketCap":359536683},{"date":"2025-09-26","current":-11.40109,"twenty":-12.682283,"median":-12.163705,"eighty":-11.408716,"marketCap":335522685},{"date":"2025-10-03","current":-11.790024,"twenty":-12.394014,"median":-12.03406,"eighty":-11.475827,"marketCap":346968609},{"date":"2025-10-10","current":-11.927294,"twenty":-12.217088,"median":-11.973051,"eighty":-11.471251,"marketCap":351008347},{"date":"2025-10-17","current":-12.506882,"twenty":-12.401641,"median":-12.018808,"eighty":-11.491079,"marketCap":368065019},{"date":"2025-10-24","current":-12.079817,"twenty":-12.247593,"median":-12.026434,"eighty":-11.561239,"marketCap":355496945},{"date":"2025-10-31","current":-12.415368,"twenty":-12.43367,"median":-12.041687,"eighty":-11.652753,"marketCap":365371860},{"date":"2025-11-07","current":-18.511527,"twenty":-12.493155,"median":-12.14464,"eighty":-11.774771,"marketCap":348090759},{"date":"2025-11-14","current":-20.046619,"twenty":-12.715838,"median":-12.201836,"eighty":-11.777822,"marketCap":376956619},{"date":"2025-11-21","current":-21.244034,"twenty":-16.587413,"median":-12.217088,"eighty":-11.811377,"marketCap":399472820},{"date":"2025-11-28","current":-23.934856,"twenty":-18.511527,"median":-12.278098,"eighty":-11.89679,"marketCap":450071024},{"date":"2025-12-05","current":-25.899155,"twenty":-20.625145,"median":-12.354359,"eighty":-11.912042,"marketCap":487007713},{"date":"2025-12-12","current":-27.217658,"twenty":-21.714928,"median":-12.472564,"eighty":-11.927294,"marketCap":511800833},{"date":"2025-12-19","current":-26.50459,"twenty":-23.934856,"median":-12.598395,"eighty":-11.934921,"marketCap":498392309},{"date":"2025-12-26","current":-29.599034,"twenty":-25.317938,"median":-12.735666,"eighty":-11.971526,"marketCap":556580244},{"date":"2026-01-02","current":-29.948841,"twenty":-26.033696,"median":-12.811928,"eighty":-12.003556,"marketCap":563158010},{"date":"2026-01-09","current":-27.984542,"twenty":-26.736001,"median":-17.717835,"eighty":-12.027959,"marketCap":526221321},{"date":"2026-01-16","current":-28.76488,"twenty":-26.943194,"median":-18.511527,"eighty":-12.038636,"marketCap":540894800},{"date":"2026-01-23","current":-31.724783,"twenty":-27.597063,"median":-20.046619,"eighty":-12.056939,"marketCap":596552825},{"date":"2026-01-30","current":-28.482344,"twenty":-28.30475,"median":-20.93459,"eighty":-12.092019,"marketCap":535581989},{"date":"2026-02-06","current":-32.101498,"twenty":-28.673392,"median":-21.418938,"eighty":-12.137776,"marketCap":603636573},{"date":"2026-02-13","current":-32.760749,"twenty":-28.899421,"median":-22.367452,"eighty":-12.188109,"marketCap":616033133},{"date":"2026-02-20","current":-32.558938,"twenty":-29.179266,"median":-23.692682,"eighty":-12.201836,"marketCap":612238268},{"date":"2026-02-27","current":-32.5993,"twenty":-29.599034,"median":-24.876643,"eighty":-12.203361,"marketCap":612997241},{"date":"2026-03-06","current":-31.684421,"twenty":-30.30403,"median":-25.616619,"eighty":-12.210987,"marketCap":595793852},{"date":"2026-03-13","current":-33.554542,"twenty":-31.627914,"median":-25.899155,"eighty":-12.217088,"marketCap":630959603},{"date":"2026-03-20","current":-32.276402,"twenty":-31.988483,"median":-26.370049,"eighty":-12.224714,"marketCap":606925456},{"date":"2026-03-27","current":-24.621582,"twenty":-31.988483,"median":-26.625677,"eighty":-12.26437,"marketCap":620586972},{"date":"2026-04-02","current":-24.902627,"twenty":-31.966957,"median":-26.235508,"eighty":-12.300976,"marketCap":627670720},{"date":"2026-04-10","current":-26.388153,"twenty":-31.886233,"median":-26.156251,"eighty":-12.33148,"marketCap":665113391},{"date":"2026-04-17","current":-28.385582,"twenty":-31.84587,"median":-26.235508,"eighty":-12.354359,"marketCap":715458604},{"date":"2026-04-24","current":-35.011617,"twenty":-31.993865,"median":-26.565134,"eighty":-12.415368,"marketCap":882467800},{"date":"2026-05-01","current":-36.076352,"twenty":-32.168769,"median":-26.669198,"eighty":-12.438246,"marketCap":909304449},{"date":"2026-05-08","current":-36.38353,"twenty":-32.30331,"median":-26.814034,"eighty":-12.506882,"marketCap":917046871},{"date":"2026-05-15","current":-23.123601,"twenty":-32.316764,"median":-26.760218,"eighty":-12.583143,"marketCap":900733639},{"date":"2026-05-22","current":-20.613207,"twenty":-32.30331,"median":-26.667619,"eighty":-12.598395,"marketCap":802946256},{"date":"2026-05-29","current":-20.2672,"twenty":-32.30331,"median":-26.565134,"eighty":-12.6289,"marketCap":789468229},{"date":"2026-06-05","current":-21.275774,"twenty":-32.281784,"median":-26.235508,"eighty":-12.715838,"marketCap":828755242},{"date":"2026-06-12","current":-21.010748,"twenty":-32.254875,"median":-25.973152,"eighty":-12.741767,"marketCap":818431648},{"date":"2026-06-18","current":-22.122388,"twenty":-32.201059,"median":-25.758446,"eighty":-12.784474,"marketCap":861733392},{"date":"2026-06-26","current":-22.821765,"twenty":-32.168769,"median":-25.603165,"eighty":-13.037355,"marketCap":888976212},{"date":"2026-07-02","current":-23.476971,"twenty":-32.141861,"median":-25.394457,"eighty":-14.887526,"marketCap":914498432},{"date":"2026-07-10","current":-24.838915,"twenty":-32.079972,"median":-25.197689,"eighty":-17.661739,"marketCap":967550238},{"date":"2026-07-17","current":-22.519929,"twenty":-32.026155,"median":-24.876643,"eighty":-18.127213,"marketCap":877218784},{"date":"2026-07-24","current":-25.486758,"twenty":-31.993865,"median":-24.857779,"eighty":-18.396949,"marketCap":992785692},{"date":"2026-07-31","current":-30.110006,"twenty":-31.988483,"median":-25.029051,"eighty":-18.623718,"marketCap":1172875066},{"date":"2026-08-07","current":-35.46944,"twenty":-32.036919,"median":-25.243817,"eighty":-19.236335,"marketCap":1381641093},{"date":"2026-08-14","current":-16.667021,"twenty":-32.036919,"median":-25.197689,"eighty":-18.062763,"marketCap":1428113677},{"date":"2026-08-21","current":-17.781418,"twenty":-31.993865,"median":-24.876643,"eighty":-17.822455,"marketCap":1523600835},{"date":"2026-08-28","current":-18.029899,"twenty":-31.988483,"median":-24.686825,"eighty":-17.939919,"marketCap":1544891890},{"date":"2026-09-04","current":-17.890599,"twenty":-31.950812,"median":-24.595973,"eighty":-17.81229,"marketCap":1532955996},{"date":"2026-09-11","current":-17.412462,"twenty":-31.886233,"median":-24.257328,"eighty":-17.792713,"marketCap":1491986843},{"date":"2026-09-18","current":-15.865106,"twenty":-31.84587,"median":-23.934856,"eighty":-17.412462,"marketCap":1359401634},{"date":"2026-09-25","current":-14.231158,"twenty":-31.724783,"median":-23.892916,"eighty":-16.881618,"marketCap":1219396815},{"date":"2026-10-02","current":-14.035386,"twenty":-31.684421,"median":-23.764083,"eighty":-16.185119,"marketCap":1202622044},{"date":"2026-10-09","current":-13.030169,"twenty":-31.657513,"median":-23.572675,"eighty":-15.865106,"marketCap":1116490046}],"updateTime":1791661169154},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LBRX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2674861892","title":"LB Pharmaceuticals Advances LB-102 into Phase 3 Schizophrenia Trial NOVA-2","url":"https://stock-news.laohu8.com/highlight/detail?id=2674861892","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674861892?lang=en_us&edition=fundamental","pubTime":"2026-10-10 20:00","pubTimestamp":1791633619,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals advances LB-102 into Phase 3 schizophrenia trial NOVA-2LB Pharmaceuticals presented new preclinical findings on LB-102’s mechanism at the 39th ECNP Congress on Oct. 10, 2026.Data in","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261010:nNDL91y8k2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","LU0314104364.USD","SG9999014039.USD","BK4112","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU2210149790.SGD","BK4007","IE00BN0W2T93.GBP","NDAQ","IE00BQXX3D17.EUR","LU2095319765.USD","BCDF","IE00BN0W2V16.EUR","IE00BQXX3C00.GBP","BK4585","BK4588","IE00BGHQF748.EUR","SG9999014013.SGD","IE00B3QW5Z07.USD","LU2210150020.SGD","SG9999014021.USD","LBRX","IE00BQXX3F31.USD","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674878892","title":"LB Pharmaceuticals Presents New Preclinical Data Supporting LB-102’s Bimodal Mechanism of Action and Highlights Ongoing Late-Stage Clinical Development Programs at the 39th ECNP Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2674878892","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674878892?lang=en_us&edition=fundamental","pubTime":"2026-10-10 20:00","pubTimestamp":1791633600,"startTime":"0","endTime":"0","summary":"NEW YORK, Oct.  10, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-im","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/10/3378442/0/en/lb-pharmaceuticals-presents-new-preclinical-data-supporting-lb-102-s-bimodal-mechanism-of-action-and-highlights-ongoing-late-stage-clinical-development-programs-at-the-39th-ecnp-co.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LBRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674861049","title":"LB Pharmaceuticals Grants 200,000-Share Option Inducement Awards to New CMO, CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2674861049","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674861049?lang=en_us&edition=fundamental","pubTime":"2026-10-10 04:42","pubTimestamp":1791578570,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals grants 200,000-share option inducement awards to new CMO, CFOLB Pharmaceuticals granted stock options to new executives Susan G. Kozauer and Joseph Miller on Oct. 9, 2026.Each optio","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261009:nNDL5DPDVh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","IE00BQXX3F31.USD","IE00BN0W2T93.GBP","BCDF","SG9999014005.SGD","BK4588","IE00BN0W2V16.EUR","BK4007","IE00BN0W2W23.USD","SG9999014039.USD","LU2210149790.SGD","LU2095319765.USD","IE00B64PRP62.GBP","IE00BQXX3D17.EUR","LU0314104364.USD","IE00B3QW5Z07.USD","LU2210150020.SGD","BK4112","NDAQ","SG9999014021.USD","IE00BQXX3C00.GBP","IE00BGHQF748.EUR","LBRX","BK4585","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674861017","title":"Lb Pharmaceuticals Reports Inducement Grants to New Employee Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2674861017","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674861017?lang=en_us&edition=fundamental","pubTime":"2026-10-10 04:42","pubTimestamp":1791578556,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261009:nTUA4MCZNK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LBRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674074861","title":"LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2674074861","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674074861?lang=en_us&edition=fundamental","pubTime":"2026-10-10 04:42","pubTimestamp":1791578520,"startTime":"0","endTime":"0","summary":"NEW YORK, Oct.  09, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-im","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/09/3378379/0/en/lb-pharmaceuticals-reports-inducement-grants-to-new-employee-under-nasdaq-listing-rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LCLG","LBRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674085408","title":"Lb Pharmaceuticals Inc : Canaccord Genuity Initiates Coverage with Buy Rating; Target Price $65","url":"https://stock-news.laohu8.com/highlight/detail?id=2674085408","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674085408?lang=en_us&edition=fundamental","pubTime":"2026-10-09 21:01","pubTimestamp":1791550860,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261009:nFWN45V1F3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","LBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674799837","title":"Canaccord Genuity Initiates LB Pharmaceuticals at Buy With $65 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2674799837","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674799837?lang=en_us&edition=fundamental","pubTime":"2026-10-09 17:20","pubTimestamp":1791537611,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals (LBRX) has an average rating of buy and mean price target of $58.36, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673566840","title":"LB Pharmaceuticals to Host In-Person and Virtual R&D Day on October 27, 2026: Advancing LB‑102 with a Focus on Schizophrenia Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2673566840","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673566840?lang=en_us&edition=fundamental","pubTime":"2026-10-06 20:00","pubTimestamp":1791288000,"startTime":"0","endTime":"0","summary":"NEW YORK, Oct.  06, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-im","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/06/3375433/0/en/lb-pharmaceuticals-to-host-in-person-and-virtual-r-d-day-on-october-27-2026-advancing-lb-102-with-a-focus-on-schizophrenia-treatment.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2294711713.HKD","LU2357125470.USD","CCO","LU0823414478.USD","LU0823414551.USD","LU2506951792.HKD","CEO","BK4009","LBRX","LU2249611893.SGD","BK4007","CFO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673084940","title":"Guggenheim stats LB Pharmaceuticals at Buy, calls best idea","url":"https://stock-news.laohu8.com/highlight/detail?id=2673084940","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673084940?lang=en_us&edition=fundamental","pubTime":"2026-10-06 04:20","pubTimestamp":1791231619,"startTime":"0","endTime":"0","summary":"Guggenheim analyst Delma Caiati initiated coverage of LB Pharmaceuticals (LBRX) with a Buy rating and $80 price target The analyst named LB a best ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/guggenheim-stats-lb-pharmaceuticals-at-buy-calls-best-idea-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/guggenheim-stats-lb-pharmaceuticals-at-buy-calls-best-idea-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LBRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673086790","title":"LB Pharmaceuticals Price Target Cut to $35.00/Share from $37.00 by Roth Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2673086790","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673086790?lang=en_us&edition=fundamental","pubTime":"2026-10-06 01:19","pubTimestamp":1791220740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LBRX/analyst-ratings","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673025707","title":"LB Pharmaceuticals downgraded to Neutral from Buy at Roth Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2673025707","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673025707?lang=en_us&edition=fundamental","pubTime":"2026-10-05 20:55","pubTimestamp":1791204929,"startTime":"0","endTime":"0","summary":"Roth Capital downgraded LB Pharmaceuticals (LBRX) to Neutral from Buy with a price target of $35, down from $37. Faster development and competitive...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lb-pharmaceuticals-downgraded-to-neutral-from-buy-at-roth-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lb-pharmaceuticals-downgraded-to-neutral-from-buy-at-roth-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672715536","title":"Needham Initiates LB Pharmaceuticals at Buy With $68 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2672715536","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672715536?lang=en_us&edition=fundamental","pubTime":"2026-10-02 17:48","pubTimestamp":1790934506,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals (LBRX)has an average rating of buy and mean price target of $58.56, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major b","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672132107","title":"LB Pharmaceuticals Initiated at Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2672132107","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672132107?lang=en_us&edition=fundamental","pubTime":"2026-10-02 17:29","pubTimestamp":1790933340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LBRX/analyst-ratings","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672713863","title":"LB Pharmaceuticals initiated with a Buy at Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2672713863","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672713863?lang=en_us&edition=fundamental","pubTime":"2026-10-02 16:55","pubTimestamp":1790931308,"startTime":"0","endTime":"0","summary":"Needham initiated coverage of LB Pharmaceuticals (LBRX) with a Buy rating and $68 price target The company’s LB-102 is an improved version of amisu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lb-pharmaceuticals-initiated-with-a-buy-at-needham-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lb-pharmaceuticals-initiated-with-a-buy-at-needham-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672718168","title":"Analyst Initiates Buy Rating on LB-102 for De-Risked Antipsychotic Profile, Multi-Indication Potential and Strong Long-Term Revenue Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2672718168","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672718168?lang=en_us&edition=fundamental","pubTime":"2026-10-02 16:35","pubTimestamp":1790930121,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals, Inc. (LBRX) has received a new Buy rating, initiated by Needham analyst, Ami Fadia. Ami Fadia has given his Buy rating due to a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-initiates-buy-rating-on-lb-102-for-de-risked-antipsychotic-profile-multi-indication-potential-and-strong-long-term-revenue-outlook-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-initiates-buy-rating-on-lb-102-for-de-risked-antipsychotic-profile-multi-indication-potential-and-strong-long-term-revenue-outlook-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LBRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672718328","title":"Lb Pharmaceuticals Inc : Needham Initiates Coverage with Buy Rating; Target Price $68","url":"https://stock-news.laohu8.com/highlight/detail?id=2672718328","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672718328?lang=en_us&edition=fundamental","pubTime":"2026-10-02 16:25","pubTimestamp":1790929528,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nFWN45O0N5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","LBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672649167","title":"Lb Pharmaceuticals Inc Files for Mixed Shelf; Size not Disclosed - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2672649167","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672649167?lang=en_us&edition=fundamental","pubTime":"2026-10-02 04:06","pubTimestamp":1790885213,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nFWN45N151:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","LBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670418185","title":"LB Pharmaceuticals’ Chief Medical Officer Susan Gani Kozauer Files Initial Beneficial Ownership Statement (Form 3)","url":"https://stock-news.laohu8.com/highlight/detail?id=2670418185","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670418185?lang=en_us&edition=fundamental","pubTime":"2026-09-25 04:27","pubTimestamp":1790281648,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals’ Chief Medical Officer Susan Gani Kozauer files initial beneficial ownership statement (Form 3)LB Pharmaceuticals filed a Form 3 naming Susan Gani Kozauer as chief medical officer, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nNDL9n9GmP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LBRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667644444","title":"Lb Pharmaceuticals Appoints Susan G. Kozauer, M.d. as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2667644444","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667644444?lang=en_us&edition=fundamental","pubTime":"2026-09-15 20:00","pubTimestamp":1789473608,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nTUA6SQT0T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LBRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667176644","title":"Press Release: LB Pharmaceuticals Appoints Susan G. Kozauer, M.D. as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2667176644","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667176644?lang=en_us&edition=fundamental","pubTime":"2026-09-15 20:00","pubTimestamp":1789473600,"startTime":"0","endTime":"0","summary":"NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (\"LB Pharmaceuticals\" or the \"Company\") (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-im","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LBRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":88,"code":"91000000","status":"200"}]}}